CCEL - Earnings announcements

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024. Net (Loss) Income The Company repo

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023. Financial Results Revenue Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022. The revenues for fiscal 2023 consisted of $30.8 million in processing and storage fee revenue, $66,000 in product revenue and $481,000 in public banking revenue compared to $29.8 million in processing and storage fee revenue, $104,000 in product revenue and $462,000 in public banking revenue for fiscal 2022. Net (Loss) Income The Company rep

OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022. Financial Results Revenue Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021. The revenues for fiscal 2022 consisted of $29.8 million in processing and storage fee revenue, $104,000 in product revenue and $462,000 in public banking revenue compared to $28.4 million in processing and storage fee revenue, $111,000 in product revenue and $376,000 in public banking revenue for fi

OLDSMAR, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2021. Visit here to read the fiscal year 2021 letter to shareholders. Financial Results Revenue Consolidated revenues for fiscal 2021 were $28.9 million compared to $31.1 million for fiscal 2020. The revenues for fiscal 2021 consisted of $28.4 million in processing and storage fee revenue, $111,000 in product revenue and $376,000 in public banking revenue compared to $29.5 million in processing and